Mumbai, June 8 -- Cell and gene therapy platform Immuneel Therapeutics is betting that a low-cost Indian model for CAR-T cancer treatment can travel beyond its home market.

The biotech firm, backed by Kiran Mazumdar-Shaw, said it is preparing to expand into other markets across West Asia and Asia-Pacific, building on what it describes as encouraging early commercial traction in India.

The company on Monday announced a Series B funding round of more than Rs.100 crore, with participation from new investors including Singularity AMC and Rainmatter by Zerodha, as well as existing investors Kiran Mazumdar-Shaw, Eight Roads Ventures and F-Prime Capital.

The funding will be used to scale up its CAR-T therapy business in India, expand internat...